Erastin: A Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small-molecule inducer of ferroptosis, characterized by iron-dependent, non-apoptotic cell death (Yang et al., 2025). It functions by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating voltage-dependent anion channels (VDAC), resulting in lethal accumulation of reactive oxygen species (ROS) and disruption of redox homeostasis. Erastin demonstrates selective cytotoxicity against tumor cells harboring oncogenic KRAS or BRAF mutations. Its specificity and reproducibility have established Erastin as a benchmark reagent in ferroptosis, cancer biology, and oxidative stress research. The compound is available from APExBIO as SKU B1524 and is widely adopted in standard oxidative cell death assays.

Biological Rationale

Ferroptosis is a regulated cell death modality distinct from apoptosis, necrosis, and autophagy. It is driven by iron-dependent accumulation of lipid peroxides on cellular membranes, particularly the plasma membrane, which leads to loss of membrane integrity and cell lysis (Yang et al., 2025). Tumor cells with mutations in the RAS-RAF-MEK signaling pathway, such as KRAS and BRAF, exhibit heightened metabolic dependency on the antioxidant glutathione (GSH) system. System Xc⁻, a cystine/glutamate antiporter, is critical for importing cystine necessary for GSH biosynthesis. Inhibition of system Xc⁻ thus selectively impairs redox homeostasis in these oncogene-driven cells, predisposing them to ferroptosis. This mechanistic vulnerability underpins Erastin's selective cytotoxicity in cancer models (APExBIO product page).

Mechanism of Action of Erastin

Erastin acts via two primary molecular mechanisms:

• Inhibition of system Xc⁻ (SLC7A11/SLC3A2 complex), blocking cystine uptake and depleting intracellular GSH.
• Modulation of the voltage-dependent anion channel (VDAC), altering mitochondrial membrane permeability and promoting ROS generation.

Erastin's blockade of cystine import leads to GSH depletion, impairing the activity of glutathione peroxidase 4 (GPX4), the principal enzyme detoxifying lipid hydroperoxides. This impairment results in the accumulation of oxidized phospholipids (oxPLs) and polyunsaturated fatty acid-phospholipids (PUFA-PLs) on the plasma membrane. Recent work highlights that lipid peroxidation increases membrane tension and, if unchecked by compensatory mechanisms such as TMEM16F-mediated lipid scrambling, leads to membrane rupture and cell death (Yang et al., 2025). Notably, Erastin induces ferroptosis in a caspase-independent fashion, distinguishing it from classical apoptotic inducers.

Evidence & Benchmarks

• Erastin induces robust ferroptosis in engineered human tumor cells and HT-1080 fibrosarcoma cells at 10 μM after 24 hours, as measured by loss of plasma membrane integrity and lipid ROS accumulation (Yang et al., 2025, Fig. 1A-B).
• TMEM16F-deficient cells exhibit increased sensitivity to Erastin-induced ferroptosis, confirming the role of plasma membrane lipid scrambling in modulating final cell death execution (Yang et al., 2025, Fig. 3D-F).
• System Xc⁻ inhibition by Erastin leads to rapid GSH depletion (<24h) and inactivation of GPX4 in RAS-mutant tumor cells, with no effect on normal cells lacking these mutations (see also: Erastin and Ferroptosis: Mechanistic Insights for Next-Gen Research).
• Erastin is insoluble in water and ethanol, but dissolves in DMSO at ≥10.92 mg/mL with gentle warming; solutions are unstable for long-term storage and must be freshly prepared (APExBIO product page).
• Combination of Erastin with TMEM16F inhibition or immune checkpoint blockade (PD-1) leads to robust tumor immune rejection in vivo, underscoring translational relevance (Yang et al., 2025, Fig. 6A-B).

Applications, Limits & Misconceptions

Erastin is primarily used to study:

• Ferroptosis pathways in RAS/BRAF-mutant tumor models.
• Redox biology and oxidative stress assays.
• Cancer therapy approaches targeting ferroptosis.
• Non-apoptotic cell death mechanisms for drug discovery.

For a detailed mechanistic context, see Erastin and the Executional Phase of Ferroptosis, which focuses on membrane lipid remodeling; this article extends by providing updated in vivo benchmarks and translational outcomes.

To explore practical workflows, Erastin: A Precision Ferroptosis Inducer for Advanced Cancer Models details experimental troubleshooting, whereas this review emphasizes the molecular determinants and recent in vivo synergies.

Common Pitfalls or Misconceptions

• Erastin is not effective in cell types lacking functional system Xc⁻ or with wild-type RAS/BRAF signaling.
• Ferroptosis induction by Erastin is caspase-independent; apoptotic markers are not reliable endpoints.
• Erastin is unstable in aqueous or ethanolic solutions and must be prepared fresh in DMSO for each experiment.
• Long-term storage of Erastin solutions (even at -20°C) results in loss of potency; only the solid form is stable.
• Erastin does not induce cell death via necrosis or autophagy and should not be used to model these pathways.

Workflow Integration & Parameters

For standard ferroptosis assays, Erastin (SKU B1524, APExBIO) is used at 10 μM for 24 hours, with treatment of engineered tumor cells (e.g., HT-1080). It is dissolved in DMSO at concentrations ≥10.92 mg/mL, using gentle warming if necessary. Solutions must be prepared immediately before use and discarded after the experiment due to instability. Storage of the powder at -20°C is recommended for long-term stability. Erastin is incompatible with water or ethanol as solvents. Experimental readouts typically include lipid ROS quantification (e.g., C11-BODIPY), GSH levels, and plasma membrane integrity assays (e.g., propidium iodide exclusion). For advanced workflows, Erastin can be combined with immune checkpoint inhibitors or TMEM16F modulators to assess in vivo tumor responses (Yang et al., 2025).

Conclusion & Outlook

Erastin remains the gold-standard ferroptosis inducer for research in iron-dependent, non-apoptotic cell death, with proven selectivity in RAS/BRAF-driven tumor models. Its mechanistic clarity and commercial availability from APExBIO have made it indispensable for cancer biology research and oxidative stress assays. Ongoing studies highlight its potential for combination strategies in cancer immunotherapy and underscore the importance of membrane lipid remodeling in ferroptosis execution. For reference protocols and ordering details, visit the Erastin product page.